Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions - Additional Information (Detail)

v3.19.2
Related Party Transactions - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Mar. 25, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Underwritten Public Offering [Member] | Common Stock [Member]            
Related Party Transaction [Line Items]            
Number of common stock issued in offering 16,666,668          
Dr. Frederick Telling, Chairman and Director [Member] | Underwritten Public Offering [Member] | Common Stock [Member]            
Related Party Transaction [Line Items]            
Number of common stock issued in offering 100,000          
Dr. Frederick Telling, Chairman and Director [Member] | Underwritten Public Offering [Member] | Short-term Warrants [Member]            
Related Party Transaction [Line Items]            
Number of warrants purchased in period 50,000          
Dr. Frederick Telling, Chairman and Director [Member] | Underwritten Public Offering [Member] | Long-term Warrants [Member]            
Related Party Transaction [Line Items]            
Number of warrants purchased in period 50,000          
Dr. Alan Joslyn, Chief Executive Officer and President [Member] | Underwritten Public Offering [Member] | Common Stock [Member]            
Related Party Transaction [Line Items]            
Number of common stock issued in offering 66,667          
Dr. Alan Joslyn, Chief Executive Officer and President [Member] | Underwritten Public Offering [Member] | Short-term Warrants [Member]            
Related Party Transaction [Line Items]            
Number of warrants purchased in period 33,333          
Dr. Alan Joslyn, Chief Executive Officer and President [Member] | Underwritten Public Offering [Member] | Long-term Warrants [Member]            
Related Party Transaction [Line Items]            
Number of warrants purchased in period 33,333          
Intrexon [Member]            
Related Party Transaction [Line Items]            
Accounts payable and accrued expenses   $ 47,448   $ 47,448   $ 39,607
Percentage of outstanding common stock   3.36% 25.40% 3.36% 25.40%  
Intrexon [Member] | Oral Mucositis ECC and Lantibiotic ECC [Member]            
Related Party Transaction [Line Items]            
Cash paid to Intrexon Corporation   $ 77,704 $ 89,216 $ 117,311 $ 159,233